Immunomodulatory Effects of 1,25-Dihydroxyvitamin D₃ on Dendritic Cells Promote Induction of T Cell Hyporesponsiveness to Myelin-Derived Antigens

Table 1

Clinical details of the patients recruited into the study.

UPN	Gender	Age	MS-type	EDSS score	Disease duration (years)	Medication
MS-DC 001	F	51	RR-MS	3	14.5	Glatiramer acetate
MS-DC 002	M	52	SP-MS	5	19	None
MS-DC 003	F	27	CIS	0	1	None
MS-DC 004	M	35	RR-MS	3	2	Natalizumab
MS-DC 005	F	35	RR-MS	3	6	Natalizumab
MS-DC 006	M	33	RR-MS	3.5	14	Natalizumab
MS-DC 007	F	42	RR-MS	2	18	IFN-β
MS-DC 008	M	45	RR-MS	2	19	None
MS-DC 009	M	32	RR-MS	2.5	1	IFN-β
MS-DC 010	M	25	RR-MS	1.5	2	IFN-β
	M/F: 6/4	Median: 35; Range: 25–52	RR/CP: 8/1	Median: 3; Range: 0–5	Median: 10; Range: 1–19

UPN, unique patient number; M, male; F, female; EDSS, expanded disability status scale; RR-MS, relapsing-remitting multiple sclerosis; SP-MS, secondary-progressive multiple sclerosis; and CIS, clinically isolated syndrome.